A detailed history of Simplex Trading, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 27,130 shares of ALLO stock, worth $61,585. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,130
Holding current value
$61,585
% of portfolio
0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.08 - $3.5 $56,430 - $94,955
27,130 New
27,130 $75,000
Q4 2023

Feb 02, 2024

BUY
$2.28 - $3.5 $46,078 - $70,735
20,210 New
20,210 $64,000
Q2 2023

Aug 04, 2023

SELL
$4.53 - $6.74 $478,041 - $711,258
-105,528 Reduced 93.1%
7,821 $38,000
Q1 2023

Apr 27, 2023

BUY
$4.92 - $8.21 $557,677 - $930,595
113,349 New
113,349 $559,000
Q3 2022

Nov 04, 2022

BUY
$10.32 - $17.28 $21,156 - $35,424
2,050 New
2,050 $22,000
Q1 2022

May 02, 2022

SELL
$7.65 - $15.29 $50,528 - $100,990
-6,605 Closed
0 $0
Q4 2021

Feb 23, 2022

BUY
$13.13 - $24.52 $32,234 - $60,196
2,455 Added 59.16%
6,605 $98,000
Q3 2021

Oct 28, 2021

SELL
$21.01 - $27.64 $4,202 - $5,528
-200 Reduced 4.6%
4,150 $110,000
Q2 2021

Aug 12, 2021

SELL
$23.49 - $35.8 $383,638 - $584,685
-16,332 Reduced 78.97%
4,350 $113,000
Q1 2021

Apr 26, 2021

BUY
$25.79 - $39.02 $514,742 - $778,800
19,959 Added 2760.58%
20,682 $730,000
Q4 2020

Feb 02, 2021

BUY
$25.24 - $43.45 $18,248 - $31,414
723 New
723 $18,000
Q2 2020

Jul 13, 2020

SELL
$18.39 - $54.04 $38,784 - $113,970
-2,109 Closed
0 $0
Q1 2020

Apr 29, 2020

BUY
$18.22 - $28.25 $38,425 - $59,579
2,109 New
2,109 $40,000
Q3 2019

Oct 15, 2019

SELL
$26.11 - $32.99 $4,099 - $5,179
-157 Closed
0 $0
Q2 2019

Jul 26, 2019

SELL
$25.56 - $31.09 $157,142 - $191,141
-6,148 Reduced 97.51%
157 $4,000
Q1 2019

Apr 18, 2019

BUY
$24.82 - $32.54 $153,586 - $201,357
6,188 Added 5288.89%
6,305 $0
Q4 2018

Jan 16, 2019

BUY
$22.5 - $33.3 $2,632 - $3,896
117 New
117 $3,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.